Compare Cassava Sciences Inc (FLNA) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs First Trust Cloud Computing ETF — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while First Trust Cloud Computing ETF trades at $137.06. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SKYY | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $155.17 |
52-Week Low | $1.09 | $104.16 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
First Trust Cloud Computing ETF (SKYY) trades at $137.24, down 1.49% today, with a bullish technical signal driven by moving averages. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights continued investor interest in technology ETFs, with SKYY being a prominent option for broad market access.
Outlook remains positive due to structural growth in cloud services, though risks include sector volatility and competitive pressures. Analyst sentiment is generally favorable, emphasizing long-term growth potential from AI and hybrid cloud trends. Investors should weigh sector momentum against valuation concerns in a high-interest-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
